January 05, 2017
Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund (“Vulpes”), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each (“Ordinary Shares”) at 5.5 pence per Ordinary Share (the “Transaction”). Following the Transaction, Vulpes (and Mr Diggle) have a beneficial interest in 53,943,715 Ordinary Shares, representing approximately 18.33% of the current issued share capital of the Company.